Alpha Tau Medical (NASDAQ:DRTS) Stock Price Up 7.1% - Should You Buy?

Key Points

• Alpha Tau Medical shares rose 7.1% on Friday, trading around $12.73 after touching a high of $12.53, though volume was well below average. The move came amid renewed investor interest in the stock.
• Analyst sentiment is mixed: HC Wainwright and Ladenburg both kept buy ratings with price targets of $15 and $14, while Zacks cut the stock to strong sell. MarketBeat shows an overall consensus rating of Hold with a $12.60 price target.
• The company recently reported a Q1 loss wider than expected, posting EPS of -$0.26 versus estimates of -$0.13. Insider selling has also been notable, with the CFO and other insiders selling shares over the past quarter.

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) traded up 7.1% on Friday . The stock traded as high as $12.53 and last traded at $12.7280. Approximately 196,591 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 591,564 shares. The stock had previously closed at $11.88.

Analyst Ratings Changes

A number of research firms recently weighed in on DRTS. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research note on Thursday. LADENBURG THALM/SH SH boosted their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, May 12th. Zacks Research cut shares of Alpha Tau Medical from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 1st. Piper Sandler upped their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a research report on Tuesday, May 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $12.60.

Alpha Tau Medical Stock Performance

The business has a 50-day moving average of $10.73 and a two-hundred day moving average of $8.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The company has a market cap of $1.21 billion, a P/E ratio of -19.84 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, sell-side analysts predict that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Insider Activity

In related news, CFO Raphi Levy sold 32,500 shares of the business's stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the transaction, the chief financial officer owned 147,680 shares in the company, valued at $1,599,374.40. The trade was a 18.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 112,270 shares of company stock valued at $1,270,923. 39.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors have recently bought and sold shares of DRTS. Apella Capital LLC acquired a new position in shares of Alpha Tau Medical during the fourth quarter worth $1,892,000. Daytona Street Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth $749,000. Mariner LLC boosted its position in shares of Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company's stock worth $620,000 after purchasing an additional 1,915 shares in the last quarter. Millennium Management LLC grew its stake in Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company's stock worth $534,000 after buying an additional 70,081 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Alpha Tau Medical during the 1st quarter worth $286,000. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.